Dr Nicole Muller-Sienerth | Laboratory Manager

Muller-Sienerth, Nicole

In her current role Nicole is responsible for several laboratory managing duties, including acting as local coordinator, supervising new starters, PhD students and contractors as well as ordering consumables and looking after equipment. Her work within the lab splits between her own research project, identifying binding partners for extracellular proteins, and providing recombinant proteins for collaborators within the Sanger Institute and outside.

As the lab manager I am responsible for the smooth running of the lab, including ordering consumables and equipment, initiating repairs, maintenance and servicing, performing local co-ordinator duties regarding Health and Safety, Permit to Work, Risk Assessments, New Starter Induction into CL2 and and their supervision. My current project involves cloning of soluble recombinant Fusion proteins, expression in mammalian cells and purification. I am working towards finding yet unknown binding partners to different types of extracellular proteins expressed on human platelets, the Malaria parasite Plasmodium falciparum etc. Using Flow Cytometry I analyse their binding to a wide range of cancer cell lines. Follow-up experiments will include Mass Spec analysis as well as using the CRISPR-Cas9 knock-out system.

The aim of my previouse project in this lab was to generate a panel of recombinant monoclonal antibodies against a library of Zebrafish cell surface proteins. This involved the expression and purification of extracellular domains of Zebrafish proteins, immunisation and hybridoma fusion, screening and cloning of recombinant monoclonal antibodies. These antibodies were validated via ELISA and immunohistology and made publicly available as plasmids on Addgene.

Publications

  • Synergistic malaria vaccine combinations identified by systematic antigen screening.

    Bustamante LY, Powell GT, Lin YC, Macklin MD, Cross N et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017;114;45;12045-12050

  • Basigin is a druggable target for host-oriented antimalarial interventions.

    Zenonos ZA, Dummler SK, Müller-Sienerth N, Chen J, Preiser PR et al.

    The Journal of experimental medicine 2015;212;8;1145-51

  • A panel of recombinant monoclonal antibodies against zebrafish neural receptors and secreted proteins suitable for wholemount immunostaining.

    Staudt N, Müller-Sienerth N, Fane-Dremucheva A, Yusaf SP, Millrine D and Wright GJ

    Biochemical and biophysical research communications 2015;456;1;527-33

  • Cloning of recombinant monoclonal antibodies from hybridomas in a single mammalian expression plasmid.

    Müller-Sienerth N, Crosnier C, Wright GJ and Staudt N

    Methods in molecular biology (Clifton, N.J.) 2014;1131;229-40

  • Development of an antigen microarray for high throughput monoclonal antibody selection.

    Staudt N, Müller-Sienerth N and Wright GJ

    Biochemical and biophysical research communications 2014;445;4;785-90

  • SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells.

    Müller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU et al.

    PloS one 2011;6;6;e21556

  • Superior serum half life of albumin tagged TNF ligands.

    Müller N, Schneider B, Pfizenmaier K and Wajant H

    Biochemical and biophysical research communications 2010;396;4;793-9

  • Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

    Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU et al.

    Journal of immunology (Baltimore, Md. : 1950) 2009;183;3;1851-61

  • Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization.

    Müller N, Wyzgol A, Münkel S, Pfizenmaier K and Wajant H

    The FEBS journal 2008;275;9;2296-304

  • Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.

    Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H et al.

    Cancer research 2008;68;2;597-604

  • Sustained JNK activation in response to tumor necrosis factor is mediated by caspases in a cell type-specific manner.

    Wicovsky A, Müller N, Daryab N, Marienfeld R, Kneitz C et al.

    The Journal of biological chemistry 2007;282;4;2174-83

  • Basigin is a druggable target for host-oriented antimalarial interventions.

    Zenonos ZA, Dummler SK, Müller-Sienerth N, Chen J, Preiser PR et al.

    The Journal of experimental medicine 2015;212;8;1145-51

  • A panel of recombinant monoclonal antibodies against zebrafish neural receptors and secreted proteins suitable for wholemount immunostaining.

    Staudt N, Müller-Sienerth N, Fane-Dremucheva A, Yusaf SP, Millrine D and Wright GJ

    Biochemical and biophysical research communications 2015;456;1;527-33

  • Development of an antigen microarray for high throughput monoclonal antibody selection.

    Staudt N, Müller-Sienerth N and Wright GJ

    Biochemical and biophysical research communications 2014;445;4;785-90

  • Cloning of recombinant monoclonal antibodies from hybridomas in a single mammalian expression plasmid.

    Müller-Sienerth N, Crosnier C, Wright GJ and Staudt N

    Methods in molecular biology (Clifton, N.J.) 2014;1131;229-40

  • SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells.

    Müller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU et al.

    PloS one 2011;6;6;e21556

  • Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.

    Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T et al.

    Journal of immunology (Baltimore, Md. : 1950) 2010;185;3;1593-605

  • Superior serum half life of albumin tagged TNF ligands.

    Müller N, Schneider B, Pfizenmaier K and Wajant H

    Biochemical and biophysical research communications 2010;396;4;793-9

  • Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2).

    Rauert H, Wicovsky A, Müller N, Siegmund D, Spindler V et al.

    The Journal of biological chemistry 2010;285;10;7394-404

  • Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.

    Berg D, Stühmer T, Siegmund D, Müller N, Giner T et al.

    The FEBS journal 2009;276;23;6912-27

  • Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

    Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU et al.

    Journal of immunology (Baltimore, Md. : 1950) 2009;183;3;1851-61

  • Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization.

    Müller N, Wyzgol A, Münkel S, Pfizenmaier K and Wajant H

    The FEBS journal 2008;275;9;2296-304

  • Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.

    Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H et al.

    Cancer research 2008;68;2;597-604

  • Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L.

    Berg D, Lehne M, Müller N, Siegmund D, Münkel S et al.

    Cell death and differentiation 2007;14;12;2021-34

  • Sustained JNK activation in response to tumor necrosis factor is mediated by caspases in a cell type-specific manner.

    Wicovsky A, Müller N, Daryab N, Marienfeld R, Kneitz C et al.

    The Journal of biological chemistry 2007;282;4;2174-83

  • A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.

    Assohou-Luty C, Gerspach J, Siegmund D, Müller N, Huard B et al.

    Journal of molecular medicine (Berlin, Germany) 2006;84;9;785-97

Muller-Sienerth, Nicole
Nicole's Timeline
2014

Laboratory Manager - Wellcome Trust Sanger Institute, Cambridge, UK

2013

maternity leave

2011

Advanced Research Assistant - Wellcome Trust Sanger Institute, Cambridge, UK: Generation of recombinant monoclonal antibodies against a library of Zebrafish cell surface proteins

2010

maternity leave

2009

PostDoc - University of Wuerzburg, Germany: Research in the field of Tumor Necrosis Factor (TNF) ligands and receptors

PhD in Biology - University of Wuerzburg, Germany: Dissertation title: ”Development of antigen-dependent activatable TNF ligand fusion proteins“

2004

Master of Science (“Diplom”) in Biology - University of Hohenheim, Germany: Master Thesis (“Diplomarbeit”): “Expression, purification and molecular interaction of a cytoplasmic fragment from the receptor CD44 with Merlin”

2003

Working student - Aventis Pharma Deutschland GmbH, Frankfurt/Main, Germany: Bacterial expression, purification and analysis of recombinant proteins